Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Colorcon
Deloitte
QuintilesIMS
Cipla

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,141,581

« Back to Dashboard

Which drugs does patent 7,141,581 protect, and when does it expire?

Patent 7,141,581 protects INLYTA and is included in one NDA.

This patent has eighty-two patent family members in fifty-one countries.

Summary for Patent: 7,141,581
Title:Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s): Bender; Steven (Oceanside, CA), Hu-Lowe; Dana (Encinitas, CA), Shalinsky; David Ray (San Diego, CA)
Assignee: Agouron Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/639,890
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,141,581
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,141,581

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF RENAL CELL CARCINOMA ➤ Sign Up
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF RENAL CELL CARCINOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,141,581

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1486 ➤ Sign Up
Argentina 035554 ➤ Sign Up
Argentina 065937 ➤ Sign Up
Austria 376543 ➤ Sign Up
Australia 5785200 ➤ Sign Up
Australia 777701 ➤ Sign Up
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
US Army
Citi
Julphar
Accenture
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.